Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice

Neuropsychopharmacology

Volumn 40, Issue 7, 2015, Pages 1569-1579

  Aida, Tomomi ^a   Yoshida, Junichi ^a   Nomura, Masatoshi ^b   Tanimura, Asami ^c   Iino, Yusuke ^a   Soma, Miho ^a   Bai, Ning ^a   Ito, Yukiko ^a   Cui, Wanpeng ^a   Aizawa, Hidenori ^a   Yanagisawa, Michiko ^a   Nagai, Terumi ^d   Takata, Norio ^d   Tanaka, Kenji F ^e   Takayanagi, Ryoichi ^b   Kano, Masanobu ^c   Götz, Magdalena ^f   Hirase, Hajime ^e   Tanaka, Kohichi ^a,g  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF MUNICH   (Germany)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; NERVE PROTEIN; PROTEIN; ROSA22 PROTEIN, MOUSE; SLC1A2 PROTEIN, MOUSE;

ANIMAL; ANXIETY; BRAIN CORTEX; COMPLICATION; CUMULATIVE TRAUMA DISORDERS; DEFICIENCY; DISEASE MODEL; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HYPERALGESIA; MALE; METABOLISM; MOUSE; NERVE DEGENERATION; NEWBORN; PATHOLOGY; SEIZURE; SYNAPSE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; ANXIETY; CEREBRAL CORTEX; CUMULATIVE TRAUMA DISORDERS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GENE EXPRESSION REGULATION; HYPERALGESIA; MALE; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PROTEINS; SEIZURES; SYNAPSES;

EID: 84939956304     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.26     Document Type: Article

References (46)

1. Adamczyk A, Gause CD, Sattler R, Vidensky S, Rothstein JD, Singer H et al (2011). Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome. Psychiatr Genet 21: 90-97.
2. Ahmari SE, Spellman T, Douglass NL, Kheirbek MA, Simpson HB, Deisseroth K et al (2013). Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science 340: 1234-1239.
3. Aida T, Ito Y, Takahashi YK, Tanaka K (2012). Overstimulation of NMDA receptors impairs early brain development in vivo. PLoS ONE 7: e36853.
4. Albin RL, Mink JW (2006). Recent advances in Tourette syndrome research. Trends Neurosci 29: 175-182.
5. Bateup HS, Johnson CA, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL (2013). Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 78: 510-522.
6. Berridge KC, Aldridge JW, Houchard KR, Zhuang X (2005). Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol 3: 4.
7. Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM et al (2013). Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci 16: 464-472.
8. Cavanna AE, Seri S (2013). Tourette's syndrome. BMJ 347: f4964.
9. Choudhury PR, Lahiri S, Rajamma U (2012). Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharmacol Biochem Behav 100: 841-849.
10. CuiW, Mizukami H, YanagisawaM, AidaT, NomuraM, IsomuraYet al (2014). Glial dysfunction in the mouse Habenula causes depressive-like behaviors and sleep disturbance. J Neurosci 34: 16273-16285.
11. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I (2012). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 15: 1173-1191.
12. Gaynor CM, Handley SL (2001). Effects of nicotine on head-shakes and tryptophan metabolites. Psychopharmacology (Berl) 153: 327-333.
13. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M et al (2013). Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 47: 175-180.
14. Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT et al (2009). Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl) 205: 203-216.
15. Handley S, Dursun S (1992). Serotonin and Tourette's syndrme: movement such as head-shakes and wet-dog shakes may model human tics. Adv Biosci 85: 235-253.
16. Hiyoshi T, Kambe D, Karasawa J, Chaki S (2014). Differential effects of NMDA receptor antagonists at lower and higher doses on basal gamma band oscillation power in rat cortical electroencephalograms. Neuropharmacology 85: 384-396.
17. Hoshina N, Tanimura A, Yamasaki M, Inoue T, Fukabori R, Kuroda T et al (2013). Protocadherin 17 regulates presynaptic assembly in topographic corticobasal Ganglia circuits. Neuron 78: 839-854.
18. Karlsson R-M, Adermark L, Molander A, Perreau-Lenz S, Singley E, Solomon M et al (2012). Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST. Neuropharmacology 63: 181-189.
19. Karlsson R-M, Tanaka K, Heilig M, Holmes A (2008). Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry 64: 810-814.
20. Karlsson R-M, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A (2009). Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 34: 1578-1589.
21. Kiryk A, Aida T, Tanaka K, Banerjee P, Wilczynski GM,Meyza K et al (2008). Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction. Neurotox Res 13: 19-30.
22. Kotermanski SE, Johnson JW (2009). Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci 29: 2774-2779.
23. Lagerström MC, Rogoz K, Abrahamsen B, Persson E, Reinius B, Nordenankar K et al (2010). VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch. Neuron 68: 529-542.
24. Langen M, Durston S, Kas MJH, Engeland H van, Staal WG (2011). The neurobiology of repetitive behavior: ⋯and men. Neurosci Biobehav Rev 35: 356-365.
25. Macrì S, Onori MP, Roessner V, Laviola G (2013). Animal models recapitulating the multifactorial origin of Tourette syndrome. Int Rev Neurobiol 112: 211-237.
26. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala H a, Gu H et al (2010). A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13: 133-140.
27. Matsugami TR, Tanemura K, Mieda M, Nakatomi R, Yamada K, Kondo T et al (2006). Indispensability of the glutamate transporters GLAST and GLT1 to brain development. Proc Natl Acad Sci USA 103: 12161-12166.
28. Molofsky A V, Krencik R, Krenick R, Ullian EM, Ullian E, Tsai H et al (2012). Astrocytes and disease: a neurodevelopmental perspective. Genes Dev 26: 891-907.
29. Mori T, Tanaka K, Buffo A, Wurst W, Kühn R, Götz M (2006). Inducible gene deletion in astroglia and radial glia - a valuable tool for functional and lineage analysis. Glia 54: 21-34.
30. Nordstrom EJ, Burton FH (2002). A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 7: 617-625.
31. Peghini P, Janzen J, Stoffel W (1997). Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J 16: 3822-3832.
32. Rubenstein JLR, Merzenich MM (2003). Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2: 255-267.
33. Saab AS, Neumeyer A, Jahn HM, Cupido A, Šimek AAM, Boele H-J et al (2012). Bergmann glial AMPA receptors are required for fine motor coordination. Science 337: 749-753.
34. Shimogori T, Lee DA, Miranda-Angulo A, Yang Y, Wang H, Jiang L et al (2010). A genomic atlas of mouse hypothalamic development. Nat Neurosci 13: 767-775.
35. Shmelkov S V, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T et al (2010). Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 16: 598-602.
36. Shprecher DR, Schrock L, Himle M (2014). Neurobehavioral aspects, pathophysiology, and management of Tourette syndrome. Curr Opin Neurol 27: 484-492.
37. Singer HS, Morris C, Grados M (2010). Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 74: 862-867.
38. Swerdlow NR, Sutherland AN (2005). Using animal models to develop therapeutics for Tourette Syndrome. Pharmacol Ther 108: 281-293.
39. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu X-Q et al (2007). Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39: 319-328.
40. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K et al (1997). Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
41. Ting JT, Feng G (2011). Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr Opin Neurobiol 21: 842-848.
42. Wang L, Simpson HB, Dulawa SC (2009). Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. Behav Pharmacol 20: 119-133.
43. Watase K, Hashimoto K, Kano M, Yamada K, Watanabe M, Inoue Y et al (1998). Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur J Neurosci 10: 976-988.
44. Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding J-D et al (2007). Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448: 894-900.
45. Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012). The role of glutamate signaling in the pathogenesis and treatment of obsessivecompulsive disorder. Pharmacol Biochem Behav 100: 726-735.
46. Yamasaki M, Okada R, Takasaki C, Toki S, Fukaya M, Natsume R et al (2014). Opposing role of NMDA receptor GluN2B and GluN2D in somatosensory development and maturation. J Neurosci 34: 11534-11548.